<DOC>
	<DOCNO>NCT00038584</DOCNO>
	<brief_summary>SCH66336 drug design block growth tumor cell encourage tumor cell death . This randomized study patient receive study drug drug . Participants study schedule surgery remove head neck cancer .</brief_summary>
	<brief_title>A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Histologicallyconfirmed stage II , III IV squamous cell carcinoma head neck . Patient 's tumor fully resectable require radiotherapy entire buccal mucosa patient treat definitive radiation therapy long adequate ( &gt; 2cm^3 ) tissue obtain posttherapy SCH66336 . ECOG Performance Status &lt; /= 2 Laboratory value ( perform within 14 day prior administration SCH 66336 ) : 1 . White blood cell count great 3.0 x 10^9/L 2 . Platelet count great equal 150 x 10^9/L 3 . Hemoglobin great equal 10 gm/dL ( 100 gm/L ) . Patients may receive transfusion and/or erythropoietin attain value . However , must stable without treatment least one week order eligible . 4 . Serum creatinine less 1.5 time upper limit normal . 5 . Total bilirubin le 1.5 time upper limit normal . 6 . SGOT SGPT ( one test need perform ) less equal 5.0 time upper limit normal . Able provide write informed consent . Negative pregnancy test ( female patient childbearing potential ) , sign informed consent prior registration . Patients may receive prior investigational therapy least 4 week must elapse recovery toxicity . No two prior chemotherapy regimens systemic disease . Patients poor medical risk nonmalignant systemic disease , well active uncontrolled infection . Uncontrolled heart disease ( symptomatic ischemic heart disease congestive heart failure , either condition variable medication requirement ) . Patients QTc prolongation baseline . Intractable vomiting ( e.g. , CTC Grade 2 high despite antiemetic medication ) medical condition could interfere take oral medication gastrointestinal absorption . Patient receive prior induction chemotherapy . Patient exhibit confusion , disorientation , history major psychiatric illness may impair patient 's understanding informed consent . Prior therapy FPT inhibitor . Patient 's life expectancy le 6 month . Patient grade 3 4 neurotoxicity previous anticancer treatment significant neuropathy cause . Patient require total parenteral nutrition lipid . Chemotherapy , radiation therapy , biologic therapy , surgery within four week prior administration SCH 66336 . Nitrosourea mitomycin C administration within 6 week SCH 66336 . Lack resolution toxic manifestation prior chemotherapy , biologic radiation therapy . Radiation therapy great 30 % bone marrow define Appendix D. ( Whole pelvic radiation alone exclusionary . ) Known HIV positivity AIDSrelated illness . Pregnancy lactation . Men woman childbearing potential use effective method contraception . Use oral contraception hormonal modality patient permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>